The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and the ...

Whether your stairs are straight, L-shaped or spiraled, these best vacuums for stairs tackle the dusty steps. Cleaning your ...

If you want to pass the GH-300 GitHub Copilot Certification exam on your first attempt, you not only need to learn the exam material, but also master how to analyze and answer GitHub Copilot exam ...

They claim to tackle every mess and reach every corner and edge, but most brands haven't really cracked the code yet.